You are here

  • Home
  • Archive
  • Volume 7, Issue 5
  • Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia

Article info

Article menu

Download PDFPDF

XML
Neurology
Protocol
Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia

Authors

  • Kaarina Kowalec Faculty of Medicine, Division of Neurology and Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancover, British Columbia, Canada PubMed articlesGoogle scholar articles
  • Elaine Kingwell Faculty of Medicine, Division of Neurology and Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancover, British Columbia, Canada PubMed articlesGoogle scholar articles
  • Robert Carruthers Faculty of Medicine, Division of Neurology and Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancover, British Columbia, Canada PubMed articlesGoogle scholar articles
  • Ruth Ann Marrie Departments of Internal Medicine and Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada PubMed articlesGoogle scholar articles
  • Sasha Bernatsky Division of Rheumatology, McGill University, Montreal, Quebec, Canada PubMed articlesGoogle scholar articles
  • Anthony Traboulsee Faculty of Medicine, Division of Neurology and Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancover, British Columbia, Canada PubMed articlesGoogle scholar articles
  • Colin J D Ross Faculty of Pharmaceutical Sciences, University of British Columbia, Vancover, British Columbia, Canada B.C. Childrens Hospital Research Institute, Vancouver, Canada PubMed articlesGoogle scholar articles
  • Bruce Carleton B.C. Childrens Hospital Research Institute, Vancouver, Canada Faculty of Medicine, Department of Pediatrics, University of British Columbia, Vancouver, Canada PubMed articlesGoogle scholar articles
  • Helen Tremlett Faculty of Medicine, Division of Neurology and Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancover, British Columbia, Canada PubMed articlesGoogle scholar articles
  1. Correspondence to Prof. Helen Tremlett; helen.tremlett{at}ubc.ca
View Full Text

Citation

Kowalec K, Kingwell E, Carruthers R, et al
Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia
BMJ Open 2017;7:e016276. doi: 10.1136/bmjopen-2017-016276

Publication history

  • Received February 4, 2017
  • Revised April 18, 2017
  • Accepted April 19, 2017
  • First published June 2, 2017.
Online issue publication 
January 10, 2022
Previous versions
Review history

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/